Nitazoxanide/Azithromycin Combination for COVID-19: A Suggested New Protocol for COVID-19 Early Management

Kelleni, Mina

doi:10.20944/preprints202004.0432.v1

Cited by 31 publications

(38 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Azithromycin in our study showed a high a nity of binding to Mpro. While initial studies after the disease outbreak indicated that azithromycin had synergistic effects with other antimalarial drugs in reducing the virus load and bringing about clinical improvement, the concern on its use for the treatment of COVID-19 is now gaining pace [Kelleni M 2020].However, a recent study conducted in France on 11 patients showed no rapid anti-viral clearance or clinical bene ts in patients with severe infection [Molina J et al 2020]. Another study (Jennifer C.E et.al.…”

Section: Discussionmentioning

confidence: 99%

Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids

Chauhan¹,

Kalra²

2020

Preprint

View full text Add to dashboard Cite

COVID-19 epidemic that commenced in Wuhan in December 2019 has spread worldwide within a few months. Currently, there are no targeted therapeutics and effective treatment options remain very limited. Mpro is a key CoV enzyme, which plays a pivotal role in viral replication and transcription, making it an attractive drug target for this virus. This study was conducted to evaluate the efficacy of flavonoids as drug target molecules against COVID-19 Mpro by molecular docking study. COVID-19 Mpro was docked with 14 flavonoid compounds as well as 4 already existing drugs and the binding energies were determined.Based on the results,we have identified two potential flavonoids with high binding capacity and possible drug candidates. This study will pave a way for doing advanced experimental research to evaluate the real medicinal potential of these compounds to cure COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids

Chauhan¹,

Kalra²

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Nitazoxanide is an antiparasitic agent which also has antiviral activities. Combined with hydroxychloroquine or azithromycin, a synergistic effect has been suggested as hydroxychloroquine and azithromycin inhibit viral entry and fusion, while nitazoxanide upregulates innate immune response to prevent ongoing viral replication in COVID‐19 133 …”

Section: Antiviral And/or Immunomodulatory Drugs Used For Viral Pneummentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

“…Lastly, the combination of nitazoxanide/azithromycin has been proposed as a potential treatment in the early phase of COVID-19 [ 78 ], since the in vitro antiviral activity of nitazoxanide against MERS-CoV and other coronaviruses [ 79 ]. However, further studies are deemed necessary to better understand these preliminary results.…”

Section: Antiviral Agentsmentioning

confidence: 99%

A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review

Monari¹,

Gentile²,

Camaioni³

et al. 2020

Life

View full text Add to dashboard Cite

Background: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? Methods: Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. Conclusions: In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence.

show abstract

Nitazoxanide/Azithromycin Combination for COVID-19: A Suggested New Protocol for COVID-19 Early Management

Cited by 31 publications

References 9 publications

Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids

Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review

Contact Info

Product

Resources

About